Effect of bevacizumab, a vascular endothelial growth factor inhibitor, on a rat model of peritoneal sclerosis

Ada S., Ersan S., Sifil A., Unlu M., KOLATAN H. E., Sert M., ...More

INTERNATIONAL UROLOGY AND NEPHROLOGY, vol.47, no.12, pp.2047-2051, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 47 Issue: 12
  • Publication Date: 2015
  • Doi Number: 10.1007/s11255-015-1116-8
  • Journal Name: INTERNATIONAL UROLOGY AND NEPHROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2047-2051
  • Keywords: Fibrosis, Growth factors, Peritoneal dialysis, Peritoneal membrane, MORPHOLOGIC CHANGES, SOLUTE TRANSPORT, DIALYSIS, MANAGEMENT, EXPRESSION, MEMBRANE, JAPAN, VEGF
  • Dokuz Eylül University Affiliated: Yes

Abstract

Purpose Peritoneal fibrosis is almost uniform feature encountered in peritoneal dialysis patients. The transition of epithelial cells to mesenchymal phenotype, neovascularization, and consequently development of peritoneal fibrosis occur due to the involvement of peritoneal membrane by various insults such as uremia itself, peritonitis attacks, and exposure to bio-incompatible peritoneal dialysis fluids. Bevacizumab is a monoclonal antihuman antibody developed against vascular endothelial growth factor and can reduce fibrosis by preventing neovascularization. There has been no study so far that demonstrates the effect of bevacizumab on peritoneal fibrosis in a rat model.